Read More

Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes

Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on key developments in 2024.

BMY

Read More

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates; Announces Workforce Reduction Of ~35%; Ended 2023 In Strong Financial Position With ~$175M In Cash; Runway Extended Into H2 2026

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation windowFocused execution on core targeted oncology

IKNA